COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,676 Articles (22,913 medRxiv, 8,763 bioRxiv)

Most recent first Previous |  Page 886: Articles 8851-8860  | Next

Spatial prediction of COVID-19 pandemic dynamics in the United States
Ak, C., Chitsazan, A. D., Gonen, M., Etzioni, R., Grossberg, A.
10.1101/2022.03.27.22271628 — Posted: 2022-04-02
COVID-19 vaccination coverage by company size and the effects of socioeconomic factors and workplace vaccination in Japan: a cohort study
Mori, K., Mori, T., Nagata, T., Ando, H., Hino, A., Tateishi, S., Tsuji, M., Muramatsu, K.
10.1101/2022.03.30.22273203 — Posted: 2022-04-02
Dupilumab use is associated with protection from COVID-19 mortality: A retrospective analysis.
Donlan, A. N., Mallawaarachchi, I., Sasson, J., Preissner, R., Loomba, J., Petri, W.
10.1101/2022.03.30.22273174 — Posted: 2022-04-02
Phase 3, multicentre, double-blind, randomised, parallel-group, placebo-controlled study of camostat mesilate (FOY-305) for the treatment of COVID-19 (CANDLE study)
Kinoshita, T., Shinoda, M., Nisizaki, Y., Shiraki, K., Hirai, Y., Kichikawa, Y., Tsushima, K., Sinkai, M., Komura, N., Yoshida, K., Kido, Y., Kakeya, H., Uemura, N., Kadota, J.
10.1101/2022.03.27.22271988 — Posted: 2022-04-02
Demonstration of antibodies against SARS-CoV-2, neutralizing or binding, in seroconversion panels after mRNA-1273, BNT-162b2 and Ad26.COV2.S vaccine administration.
Belda, F., Mora, O., Lopez-Martinez, M., Torres, N., Vivanco, A., Marfil, S., Pradenas, E., Massanella, M., Blanco, J., Christie, R., Crowley, M.
10.1101/2022.03.28.22272552 — Posted: 2022-04-02
Association of Mass Distribution of Rapid Antigen Tests and SARS-CoV-2 Prevalence: Results from NIH-CDC funded Say Yes! Covid Test program in Michigan
Soni, A., Herbert, C., Baek, J., Shi, Q., Marquez, J., Harman, E., Kheterpal, V., Nowak, C., Suvarna, T., Lin, H., Heetderks, W., Zai, A., Cohen-Wolkowiez, M., Corbie-Smith, G., Kibbe, W., Gerber, B. S., Hafer, N., Barton, B., Broach, J., McManus, D.
10.1101/2022.03.26.22272727 — Posted: 2022-04-02
Estimating epidemiological quantities from repeated cross-sectional prevalence measurements
Abbott, S., Funk, S.
10.1101/2022.03.29.22273101 — Posted: 2022-04-02
Declining Course of Humoral Immune Response in Initially Responding Kidney Transplant Recipients after Repeated SARS-CoV-2 Vaccination
Ronicke, S., Osmanodja, B., Budde, K., Jens, A., Hammett, C., Koch, N., Zukunft, B., Bachmann, F., Choi, M., Weber, U., Eberspaecher, B., Hofmann, J., Grunow, F., Mikhailov, M., Halleck, F., Schrezenmeier, E.
10.1101/2022.03.29.22272858 — Posted: 2022-04-02
Androgen receptor polyQ alleles and COVID-19 severity in men: a replication study
Lopez-Rodriguez, R., Ruiz-Hornillos, J., Corton, M., Almoguera, B., Minguez, P., Perez-Tomas, M. E., Barreda-Sanchez, M., Mancebo, E., Ondo, L., Martinez-Ramas, A., Fernandez-Caballero, L., the STOP_Coronavirus Study Group, , Paz-Artal, E., Guillen-Navarro, E., Ayuso, C.
10.1101/2022.03.25.22271678 — Posted: 2022-04-02
Lessons from a pandemic
Eggli, Y., Rousson, V.
10.1101/2022.03.30.22273190 — Posted: 2022-04-02

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).